2.2 Device Selection Framework
Key Takeaways
- Device Assessment and Selection is a 14% VA-BC blueprint domain focused on matching therapy, duration, vessel health, and patient risk.
- Use the least invasive device that can safely deliver the prescribed therapy for the expected duration.
- Midlines remain peripheral devices; vesicants, extreme pH, and high osmolarity therapies require central access planning.
- MAGIC-style logic separates peripheral IV, midline, and PICC decisions by duration, infusate, setting, and clinical need.
- SAVE-CVAD-style thinking adds vein preservation, vessel health, lumen minimization, and the <=45% PICC ratio.
Start with the therapy, then choose the device
Device Assessment and Selection accounts for 14% of the VA-BC blueprint. The safest exam answer usually begins with the therapy and the patient, not with the device the clinician likes most. Ask four questions: How long is therapy expected to last? Is the infusate appropriate for peripheral administration? Does the patient need reliable intermittent, continuous, urgent, or high-flow access? Does the patient have vessel preservation needs, lymphedema risk, central stenosis, thrombosis history, or prior device failure?
The core rule is to use the least invasive device that can safely meet the clinical requirement. This does not mean avoiding central access when it is indicated. It means a central device should have a reason: central infusate, expected duration, poor peripheral options, need for specific hemodilution, hemodynamic monitoring, dialysis flow, or long-term therapy pattern. Conversely, a midline or peripheral IV should not be stretched beyond its role just to avoid a central line.
Device roles to know
| Therapy pattern or need | Device commonly considered | Selection logic |
|---|---|---|
| Brief peripheral-compatible therapy | Short peripheral IV | Least invasive and fast to place |
| Nonvesicant, nonirritant therapy for about 1 to 4 weeks | Midline | Longer peripheral dwell without a central tip |
| Central infusate or longer therapy needing reliable central access | PICC | Peripherally inserted with central tip at or near the CAJ |
| Acute critical central access | Non-tunneled CVC | Short-term central access in monitored settings |
| Frequent long-term access | Tunneled CVC | External catheter with tunneled tract and cuff |
| Intermittent long-term therapy such as some oncology regimens | Implanted port | Fully subcutaneous between accesses |
| Long-term hemodialysis | AV fistula preferred when feasible | High-yield emphasis for patency and low infection risk |
| Dialysis when fistula or graft is not usable or feasible | Tunneled cuffed HD catheter | Bridge or alternative, not the same as a PICC |
A midline catheter terminates peripherally, so it is not appropriate for vesicants, high-risk irritants, total parenteral nutrition that requires central administration, or therapies outside the peripheral range described in the VA-BC preparation sources. A PICC is central and may fit longer therapy or central infusates, but it also uses arm and central veins that may be needed later.
A non-tunneled CVC is not a long-term convenience line; it is generally an acute central option. A tunneled CVC or implanted port better matches long-term access, with the port especially useful when access is intermittent and the patient does not need an external catheter every day.
MAGIC and SAVE-CVAD style logic
MAGIC, the Michigan Appropriateness Guide for Intravenous Catheters, is best treated as a structured appropriateness framework for choosing among peripheral IVs, midlines, and PICCs. In exam scenarios, MAGIC-style thinking weighs duration, infusate, patient setting, and whether a PICC is justified instead of a less invasive option. For example, a short course of peripheral-compatible medication should not become a PICC by default. A several-week course may move the answer toward midline or PICC depending on duration and infusate.
SAVE-CVAD-style logic adds vessel health and preservation to the device choice. For PICCs, the VA-BC preparation sources highlights a vessel-to-catheter ratio of <=45%. It also reinforces the importance of selecting the fewest lumens needed. A single lumen is preferred when it can safely deliver the therapy; extra lumens are justified by simultaneous incompatible infusions or clear clinical need, not convenience. More lumens usually mean more catheter material in the vein and more connection points to manage.
Renal preservation and dialysis access
Renal preservation is one of the easiest places to lose points by overselecting a PICC. In chronic kidney disease or likely future dialysis, protect upper extremity and central veins whenever possible. A PICC may contribute to stenosis or thrombosis that limits future arteriovenous fistula or graft options. A subclavian CVC is also concerning for central vein stenosis. If the therapy is peripheral-compatible and expected to last several weeks, a midline may preserve future dialysis access better than a PICC. If the patient needs hemodialysis, remember that a PICC is not a hemodialysis device and does not provide the required flow.
For long-term hemodialysis, the source materials emphasize arteriovenous fistula as the preferred access when feasible, with grafts and tunneled cuffed hemodialysis catheters used when fistula creation, maturation, or use is not possible. Non-tunneled hemodialysis catheters are temporary solutions for acute needs.
Putting the framework together
A strong selection answer states why the chosen device fits the therapy and why the rejected devices do not. If the drug is a vesicant or requires central dilution, a short peripheral IV or midline is not enough. If therapy is brief and peripheral-compatible, a PICC is more invasive than necessary.
If the patient has bilateral arm contraindications from lymphedema or surgical history, an alternate central route such as a tunneled internal jugular CVC may be more appropriate than forcing an arm PICC. If rapid resuscitation is the priority, a large-bore short peripheral catheter may outperform a longer, smaller central catheter for flow. Device selection is therefore a chain of constraints: therapy, duration, vessel, patient history, access frequency, lumen count, and preservation.
A patient with stage 4 chronic kidney disease needs three weeks of nonvesicant IV antibiotics and has a compressible upper-arm vein that can support peripheral dwell. Which choice best follows vein-preservation logic?
Which statement best reflects MAGIC and SAVE-CVAD style decision-making for an adult access request?